CXCL9 Cancer Research Results
CXCL9, CXCL9: Click to Expand ⟱
| Source: |
| Type: |
CXCL9 (also known as monokine induced by gamma interferon, MIG) is a chemokine that plays a critical role in immune surveillance by recruiting activated T cells, natural killer (NK) cells, and other leukocytes to the tumor microenvironment. Its expression is often regulated by interferon‐γ (IFN-γ) and other inflammatory cytokines.
– CXCL9 is often expressed by both tumor and stromal cells.
– High expression can be found in tumor microenvironments.
– Elevated CXCL9 expression is generally linked to a favorable prognosis due to effective immune cell recruitment.
Strategies that boost CXCL9 expression or restore its activity in immunologically "cold" tumors are being explored as potential means to enhance the efficacy of immunotherapies.
|
Scientific Papers found: Click to Expand⟱
| - |
in-vitro, |
Melanoma, |
B16-F10 |
|
|
|
OS↑, prolonged the mouse survival rate
DCells↑,
T-Cell↑,
Apoptosis↑,
IL1↑,
IFN-γ↓, most of cytokines were decreased
IL10↑,
TumCG↓, grow slowed
ROS↑, Phagocyte activity, ROS release and interleukin-1β (IL-1β) production were significantly promoted after continuous exposure to 50 Hz LF-MF (1mT)
TumCP↓, LF-MF inhibits the proliferation of B16-F10 cells
TumCCA↑, the S-phase rate was significantly decreased from 40.76% to 37.24% and the G2/M-phase rate was significantly increased from 8.9% to 11.6%
ChrMod↑, Compared with control cells, the treated cells were characterized by the breaking down of chromatin (white arrow) and black granule accumulation (black arrow).
CXCL9↓, in tumor-bearing mice groups, most of cytokines were decreased after LF-MF exposure, including KC, CCL1, IFN-γ, CXCL9, CXCL12, TREM-1, CCL12, IL-1rα and IL-16.
CXCL12↓,
CD4+↑, After LF-MF exposure, the proportions of CD3+, CD3 + CD4+ and CD3 + CD8+ T cells in tumor-bearing mice were increased to 24.0%, 13.28% and 7.46%, respectively
CD8+↑,
other↑, Median skin sulforaphane levels on day 28 were 0.0 ng/g, 3.1 ng/g, and 34.1 ng/g for 50, 100, and 200 µmol, respectively
decorin↑,
*toxicity↓, Oral BSE-SFN is well-tolerated at daily doses up to 200 µmol and achieves dose-dependent levels in plasma and skin.
IP-10/CXCL-10↓,
MCP1↓,
CXCL9↓,
MIP-1β↓,
IFN-γ↓,
Showing Research Papers: 1 to 2 of 2
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
ROS↑, 1,
Cell Death ⓘ
Apoptosis↑, 1,
Transcription & Epigenetics ⓘ
ChrMod↑, 1, other↑, 1,
Cell Cycle & Senescence ⓘ
TumCCA↑, 1,
Proliferation, Differentiation & Cell State ⓘ
TumCG↓, 1,
Migration ⓘ
CXCL12↓, 1, decorin↑, 1, TumCP↓, 1,
Immune & Inflammatory Signaling ⓘ
CD4+↑, 1, CXCL9↓, 2, DCells↑, 1, IFN-γ↓, 2, IL1↑, 1, IL10↑, 1, IP-10/CXCL-10↓, 1, MCP1↓, 1, MIP-1β↓, 1, T-Cell↑, 1,
Functional Outcomes ⓘ
OS↑, 1,
Infection & Microbiome ⓘ
CD8+↑, 1,
Total Targets: 21
Pathway results for Effect on Normal Cells:
Functional Outcomes ⓘ
toxicity↓, 1,
Total Targets: 1
Scientific Paper Hit Count for: CXCL9, CXCL9
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1093 State#:% Dir#:1
wNotes=on sortOrder:rid,rpid
Home Page